GSK Venture Fund Selects Neurostim Device Maker SetPoint Medical As First Investment

A $50 million venture fund set up by pharmaceutical giant GlaxoSmithKline has chosen vagus nerve stimulation device start-up SetPoint Medical, a company currently focused on treatments for autoimmune diseases, as its first investment. The move highlights the growing importance of device-mediated therapies for a wide range of common, chronic conditions.

In a concerted effort to capitalize on the red-hot global opportunity for neuromodulation therapy, used to treat patients with chronic pain and other debilitating conditions, Action Potential Venture Capital (APVC) Ltd., a new $50 million strategic venture capital fund from pharmaceutical giant GlaxoSmithKline PLC (GSK), has chosen as its first investment neuromodulation device company SetPoint Medical Corp. of Valencia, CA, which will receive $5 million from the APVC fund.

The investment is unique in that it brings a major pharmaceutical market player into the neuromodulation device field, and it illustrates the growing importance of device-mediated therapies for a wide range of common, chronic conditions. (See also Also see "Neuromodulation Market: Innovation Brings High-Growth Rewards" - Medtech Insight, 27 March, 2013..) However, GSK is not the first drug company to recognize the potential of the neurostim device space. Merck & Co. Inc.’s Global Health Innovation Fund recently participated in a $40 million Series A funding round for electroCore LLC, a New Jersey-based start-up developing a noninvasive, patient-administered vagus nerve stimulation (VNS) device for the treatment of cluster headaches and migraines as well as other chronic conditions. (See Also see "Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market" - Medtech Insight, 26 April, 2013..) Merck, which invested $12

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

More from Business

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By 

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.